Codexis, Inc.
Key Metrics
- Previous Close
- $1.60
- 52-Week Range
- $0.96 – $3.06
- Market Cap
- $173.02M
- P/E (TTM)
- —
- EPS (TTM)
- -0.33
- Dividend Yield
- —
Advanced Metrics
- Price/Book
- 4.38
- PEG Ratio
- 13.53
- Return on Equity
- -69.36%
- Return on Assets
- -11.74%
- Gross Margin
- 24.27%
- Operating Margin
- -75.29%
- Profit Margin
- -39.55%
- Current Ratio
- 3.06
- Debt/Equity
- 2.20
- Total Debt
- $72.59M
- Free Cash Flow
- $2.13M
- Revenue Growth
- -2.70%
- Earnings Growth
- —
- Enterprise Value
- $190.69M
Market Snapshot
About
Codexis, Inc. is a protein engineering company that develops and commercializes custom enzymes for pharmaceutical, food, and industrial applications. Headquartered in Redwood City, California, Codexis utilizes its proprietary CodeEvolver protein engineering platform to create novel biocatalysts that enable more efficient, sustainable, and cost-effective manufacturing processes. The company's technology combines computational design, high-throughput screening, and directed evolution to optimize enzyme performance for specific customer applications. Codexis serves pharmaceutical companies by developing enzymatic processes for manufacturing active pharmaceutical ingredients (APIs) and intermediates, often replacing traditional chemical synthesis routes with greener alternatives. The company also applies its technology to food and nutrition applications, creating enzymes for improved manufacturing processes. Codexis operates through both product sales and collaborative research partnerships with major pharmaceutical and chemical companies. The company's platform addresses growing industry demand for sustainable manufacturing solutions and has demonstrated capabilities across diverse chemistry applications.